Low AST Symptoms: Causes, Signs & What to Do
Low AST is rarely a concern on its own but can reflect vitamin B6 deficiency or, paradoxically, end-stage liver disease. This page covers the specific symptoms, likely causes, normal ranges, and when to act.
Low aspartate aminotransferase (AST, below 10 U/L) is infrequently flagged and is almost never the primary concern on a metabolic panel. Like low ALT, it can reflect vitamin B6 deficiency — since AST also requires pyridoxal phosphate (the active form of B6) as a cofactor. The paradoxical normalization of AST in end-stage liver disease, where the hepatocyte pool is too depleted to release enzyme, is a more serious finding. See the Aspartate Transaminase biomarker overview for how AST is measured.
What Low AST Means
AST requires pyridoxal phosphate as an enzymatic cofactor. When B6 is deficient, both AST and ALT activity fall. Because AST is found in multiple tissues, it can also be low simply due to reduced cell turnover or as a normal variant in people with low skeletal muscle mass.
The clinically important scenario is in known liver disease: if AST was previously elevated but has normalized — without any treatment — this may indicate burned-out cirrhosis where functional hepatocyte mass is severely depleted. This pattern is a poor prognostic sign.
Symptoms of Low AST
Low AST itself does not produce direct symptoms. The underlying cause may cause:
Vitamin B6 deficiency signs:
- Peripheral neuropathy — numbness, tingling, or burning in extremities
- Glossitis (painful, inflamed tongue) and cheilosis (cracks at lip corners)
- Microcytic or normocytic anemia
- Seborrheic dermatitis
- Irritability and confusion
Advanced liver disease (if AST falls paradoxically in known cirrhosis):
- Jaundice
- Ascites and peripheral edema
- Hepatic encephalopathy
- Coagulopathy (prolonged bleeding, easy bruising)
What Causes Low AST
- Vitamin B6 (pyridoxine) deficiency — direct reduction of enzyme activity through cofactor depletion
- End-stage liver disease — paradoxical normalization when functional hepatocyte mass is exhausted
- Low skeletal muscle mass (sarcopenia, frailty) — AST is released from muscle; very low mass means less baseline enzyme in circulation
- Uremia from kidney failure (can modestly suppress aminotransferase activity)
- Hemodialysis (dilutional and amino acid depletion effects)
Normal AST Levels
| Group | Reference Range | |---|---| | Men | 10-40 U/L | | Women | 10-35 U/L | | Low concern threshold | Below 10 U/L |
When to See Your Care Team
Book a 1:1 consultation with a licensed care team lead if low AST accompanies symptoms of peripheral neuropathy, anemia, or skin changes — these may point to B6 deficiency. If the low AST occurs in someone with known liver disease and represents a drop from previously elevated values, assess for disease progression. In healthy people without symptoms, isolated low AST is rarely clinically significant.
Frequently Asked Questions
Is low AST a marker of liver disease?
Low AST does not directly reflect liver function — it is not a measure of hepatic synthetic capacity. In an otherwise healthy person, low AST is usually a nutritional variant. The concern arises only in the specific scenario of known liver disease where normalization of previously elevated enzymes suggests depletion of functional liver cells.
Why does vitamin B6 deficiency lower AST?
AST is a pyridoxal phosphate-dependent enzyme — it requires B6 in its active form to catalyze the transamination reaction. When B6 is depleted, AST and ALT cannot function at normal capacity, and serum activity falls. This is one reason that nutritional assessment (B6, B12, folate) is part of the workup when both aminotransferases are unexpectedly low.
Can high-dose vitamin B6 cause problems?
Paradoxically, very high-dose B6 supplementation (above 100-200 mg/day chronically) can itself cause peripheral neuropathy — the same symptom as B6 deficiency. The therapeutic range for B6 is narrow; supplementation should aim to correct documented deficiency without exceeding 50-100 mg/day in most adults.
